https://childrenshealthdefense.org/defender/fda-covid-vaccine-booster-omicron-variant/
The U.S. Food and Drug Administration (FDA) advised COVID-19 vaccine manufacturers on June 30 that any modifications to booster shots for fall will need to target Omicron subvariants BA.4 and BA.5, which account for more than half of new virus cases in the U.S.
Original vaccines based on the Wuhan strain that is no longer circulating will be used for anyone getting their primary series of shots.
The FDA’s announcement came a day after the Biden administration said it had already entered into a $3.2 billion deal with Pfizer to purchase 105 million doses of its COVID-19 vaccine for a fall vaccination campaign. The announcement said these vaccines will include supplies of new unauthorized bivalent boosters containing the original Wuhan variant and BA.4 and BA.5 Omicron subvariants.
In a press release, Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, said manufacturers seeking to update current COVID-19 vaccines were advised they should “develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two-component (bivalent) booster vaccine so that the modified vaccines can potentially be used starting in early to mid-fall 2022.”